Bryce, A. H., Touya, M., Nimke, D., Young, C., Shao, S., Rozario, N., Kamdar, P., Ivanova, J. I., Varghese, I., Herrmann, J. (2025). Cardiovascular (CV) event risk in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate (AA) in the United States (US).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.5041